Thalidomide News and Research

RSS
Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.
Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

New method could help identify 'handedness' of different molecules in mixture

New method could help identify 'handedness' of different molecules in mixture

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Three-drug combination produces better results in multiple myeloma patients

Three-drug combination produces better results in multiple myeloma patients

Study reveals why survival for blood cancer patients still varies between regions within Europe

Study reveals why survival for blood cancer patients still varies between regions within Europe

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Tel Aviv University pinpoints mechanism that causes rare and severe congenital syndrome

Tel Aviv University pinpoints mechanism that causes rare and severe congenital syndrome

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Combination of anti-nausea drug and turmeric spice target cancer cells

Combination of anti-nausea drug and turmeric spice target cancer cells

Researchers develop new method that creates libraries of drug candidates, accelerate drug discovery

Researchers develop new method that creates libraries of drug candidates, accelerate drug discovery

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

European Commission amends marketing authorisation for Celgene's REVLIMID

European Commission amends marketing authorisation for Celgene's REVLIMID

New combination therapies with anti-sickling capabilities needed for sickle cell disease

New combination therapies with anti-sickling capabilities needed for sickle cell disease

National Birth Defects Prevention Network honors BU researcher with Godfrey P. Oakley, Jr., Award

National Birth Defects Prevention Network honors BU researcher with Godfrey P. Oakley, Jr., Award